Combination of oral temozolomide and etoposide as palliative chemotherapy for recurrent or progressive neuroblastoma

Authors:
Publisher website
Google Scholar
Abstract
We retrospectively analyzed the clinical outcomes of seven patients receiving palliative treatment with oraltemozolomide (TMZ)/etoposide (ETP) for recurrent or progressive neuroblastoma (NB). Patients received a median of three cycles of TMZ/ETP. One patient achieved complete response (CR), three showed stable disease, and three showed progressive disease. The median time to progression in the six patients without achieving CR was 82 days excluding one achieving CR for >222 days. Grade 3 hematological toxicities were common but manageable, and no patients experienced severe non-hematological toxicity. TMZ/ETP is a feasible palliative chemotherapy option for certain patients with recurrent or progressive NB.

This publication has 19 references indexed in Scilit: